Latest & greatest articles for hypertension

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hypertension or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hypertension and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hypertension

1. Distribution of diabetes, hypertension and non-communicable disease risk factors among adults in rural Bangladesh: a cross-sectional survey

Distribution of diabetes, hypertension and non-communicable disease risk factors among adults in rural Bangladesh: a cross-sectional survey 30498584 2018 12 03 2059-7908 3 6 2018 BMJ global health BMJ Glob Health Distribution of diabetes, hypertension and non-communicable disease risk factors among adults in rural Bangladesh: a cross-sectional survey. e000787 10.1136/bmjgh-2018-000787 Non-communicable diseases (NCDs) are increasing in low-income settings. We conducted a survey of risk factors (...) , intermediate hyperglycaemia, hypertension and NCD risk factors by age, sex and wealth. Women had higher levels of overweight or obesity and lower levels of physical activity and fruit and vegetable consumption than men; 63% of men used tobacco compared with 41.3% of women. Overweight or obesity and abdominal obesity (waist to hip ratio) increased with socioeconomic status (least poor vs most poor: OR (95% CI) 3.21 (2.51 to 4.11) for men and 2.83 (2.28 to 3.52) for women). Tobacco use, passive smoke

BMJ global health2018 Full Text: Link to full Text with Trip Pro

2. Sildenafil (Revatio and Viagra): reports of persistent pulmonary hypertension of the newborn (PPHN) following in-utero exposure in a clinical trial on intrauterine growth restriction

Sildenafil (Revatio and Viagra): reports of persistent pulmonary hypertension of the newborn (PPHN) following in-utero exposure in a clinical trial on intrauterine growth restriction Sildenafil (Revatio and Viagra): reports of persistent pulmonary hypertension of the newborn (PPHN) following in-utero exposure in a clinical trial on intrauterine growth restriction - GOV.UK GOV.UK uses cookies to make the site simpler. Search Sildenafil (Revatio and Viagra): reports of persistent pulmonary (...) hypertension of the newborn (PPHN) following in-utero exposure in a clinical trial on intrauterine growth restriction Sildenafil is not authorised for use in pregnancy for the treatment of intrauterine growth restriction. The STRIDER clinical trial, which was studying the use of sildenafil in pregnancy for intrauterine growth restriction, has been prematurely discontinued due to a higher incidence of persistent pulmonary hypertension of the newborn (PPHN) and neonatal mortality in the sildenafil arm

MHRA Drug Safety Update2018

3. Effect of liraglutide on ambulatory blood pressure in patients with hypertension and type 2 diabetes: A randomized, double-blind, placebo-controlled trial

Effect of liraglutide on ambulatory blood pressure in patients with hypertension and type 2 diabetes: A randomized, double-blind, placebo-controlled trial 30242948 2018 10 23 1463-1326 2018 Sep 22 Diabetes, obesity & metabolism Diabetes Obes Metab Effect of liraglutide on ambulatory blood pressure in patients with hypertension and type 2 diabetes: A randomized, double-blind, placebo-controlled trial. 10.1111/dom.13541 To assess the effect of liraglutide on 24-hour ambulatory blood (...) pressure and heart rate in patients with hypertension (pre- and stage 1 hypertension) and inadequately controlled Type 2 diabetes (glycated haemoglobin 7%-10% [53-86 mmol/mol]). Eligible patients for this investigator-initiated, parallel-group, randomized, double-blind trial were on stable background antihyperglycaemic therapy excluding insulin, glucagon-like peptide-1 receptor agonists and dipeptidyl-peptidase-4 inhibitors. Participants were centrally randomized in a 1:1 ratio to daily liraglutide 0.6 mg

EvidenceUpdates2018

4. The Impact of Pulmonary Hypertension in Preterm Infants with Severe Bronchopulmonary Dysplasia through 1 Year

The Impact of Pulmonary Hypertension in Preterm Infants with Severe Bronchopulmonary Dysplasia through 1 Year 30172426 2018 10 26 1097-6833 2018 Aug 29 The Journal of pediatrics J. Pediatr. The Impact of Pulmonary Hypertension in Preterm Infants with Severe Bronchopulmonary Dysplasia through 1 Year. S0022-3476(18)30940-5 10.1016/j.jpeds.2018.07.035 To assess the effect of pulmonary hypertension on neonatal intensive care unit mortality and hospital readmission through 1 year of corrected age (...) in a large multicenter cohort of infants with severe bronchopulmonary dysplasia. This was a multicenter, retrospective cohort study of 1677 infants born <32 weeks of gestation with severe bronchopulmonary dysplasia enrolled in the Children's Hospital Neonatal Consortium with records linked to the Pediatric Health Information System. Pulmonary hypertension occurred in 370 out of 1677 (22%) infants. During the neonatal admission, pulmonary hypertension was associated with mortality (OR 3.15, 95% CI 2.10

EvidenceUpdates2018

5. Dietary Approaches to Stop Hypertension Diet and Activity to Limit Gestational Weight: Maternal Offspring Metabolics Family Intervention Trial, a Technology Enhanced Randomized Trial

Dietary Approaches to Stop Hypertension Diet and Activity to Limit Gestational Weight: Maternal Offspring Metabolics Family Intervention Trial, a Technology Enhanced Randomized Trial 30262148 2018 11 10 1873-2607 55 5 2018 Nov American journal of preventive medicine Am J Prev Med Dietary Approaches to Stop Hypertension Diet and Activity to Limit Gestational Weight: Maternal Offspring Metabolics Family Intervention Trial, a Technology Enhanced Randomized Trial. 603-614 S0749-3797(18)32025-7 (...) Dietary Approaches to Stop Hypertension diet and physical activity coaching that was received as three individual and six group counseling sessions by phone and webinar. A commercially available smartphone application was used for self-monitoring diet and physical activity. Telephone, text message prompts, and e-mail reminders encouraged adherence and website viewing. Usual-care, "web-watcher" participants were e-mailed biweekly newsletters and publicly available maternity website links. The primary

EvidenceUpdates2018

6. Somatostatin as Inflow Modulator in Liver-transplant Recipients With Severe Portal Hypertension: A Randomized Trial

Somatostatin as Inflow Modulator in Liver-transplant Recipients With Severe Portal Hypertension: A Randomized Trial 30256226 2018 09 26 1528-1140 2018 Sep 21 Annals of surgery Ann. Surg. Somatostatin as Inflow Modulator in Liver-transplant Recipients With Severe Portal Hypertension: A Randomized Trial. 10.1097/SLA.0000000000003062 To investigate the safety and efficacy of somatostatin as liver inflow modulator in patients with end-stage liver disease (ESLD) and clinically significant portal (...) hypertension (CSPH) undergoing liver transplantation (LT) (ClinicalTrials.gov number,01290172). In LT, portal hyperperfusion can severely impair graft function and survival, mainly in cases of partial LT. Thirty-three patients undergoing LT for ESLD and CSPH were randomized double-blindly to receive somatostatin or placebo (2:1). The study drug was administered intraoperatively as 5-mL bolus (somatostatin: 500 μg), followed by a 2.5 mL/h infusion (somatostatin: 250 μg/h) for 5 days. Hepatic and systemic

EvidenceUpdates2018

7. Spironolactone is effective for treating resistant hypertension

Spironolactone is effective for treating resistant hypertension Signal - Spironolactone is effective for treating resistant hypertension Dissemination Centre Discover Portal NIHR DC Discover Spironolactone is effective for treating resistant hypertension Published on 1 December 2015 This trial investigated which drug is best added to high blood pressure (hypertension) treatment if blood pressure has not come down to normal levels after taking three blood pressure lowering drugs. Such “resistant (...) hypertension” accounts for around 10% of all people who have hypertension. The study found that adding spironolactone to the existing three-drug regimen was the most effective treatment and was well-tolerated by patients. Spironolactone is currently recommended by NICE at this fourth stage of treatment, but at half the dose used in this study. The higher dose will increase the cost of prescribing slightly. Potassium levels need to be monitored when using spironolactone as there is a risk they can rise

NIHR Dissemination Centre2018

8. Idiopathic intracranial hypertension

Idiopathic intracranial hypertension Idiopathic intracranial hypertension - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Idiopathic intracranial hypertension Last reviewed: September 2018 Last updated: October 2018 Summary The most popular hypothesis is that idiopathic intracranial hypertension (IIH) is a syndrome of reduced cerebrospinal fluid absorption. Clinical features include headaches, pulse-synchronous (...) intracranial pressure, and instituting a low-sodium weight-reduction diet plus acetazolamide when indicated. Therapy can be given to reverse and prevent loss of vision. Definition Idiopathic intracranial hypertension (IIH), also known as pseudotumor cerebri, is a disorder of increased intracranial pressure that occurs mainly in overweight women of childbearing years, often in the setting of weight gain. Wall M. Idiopathic intracranial hypertension. Neurol Clin. 2010;28:593-617. http://www.ncbi.nlm.nih.gov

BMJ Best Practice2018

9. Association of Clinical and Social Factors With Excess Hypertension Risk in Black Compared With White US Adults.

Association of Clinical and Social Factors With Excess Hypertension Risk in Black Compared With White US Adults. Importance: The high prevalence of hypertension among the US black population is a major contributor to disparities in life expectancy; however, the causes for higher incidence of hypertension among black adults are unknown. Objective: To evaluate potential factors associated with higher risk of incident hypertension among black adults. Design, Setting, and Participants: Prospective (...) cohort study of black and white adults selected from a longitudinal cohort study of 30 239 participants as not having hypertension at baseline (2003-2007) and participating in a follow-up visit 9.4 years (median) later. Exposures: There were 12 clinical and social factors, including score for the Southern diet (range, -4.5 to 8.2; higher values reflect higher level of adherence to the dietary pattern), including higher fried and related food intake. Main Outcomes and Measures: Incident hypertension

JAMA2018

10. Optimal Systolic Blood Pressure Target in Apparent Resistant and Non-Resistant Hypertension: A Pooled Analysis of Patient-Level Data from Sprint and ACCORD

Optimal Systolic Blood Pressure Target in Apparent Resistant and Non-Resistant Hypertension: A Pooled Analysis of Patient-Level Data from Sprint and ACCORD 30142317 2018 09 25 1555-7162 2018 Aug 22 The American journal of medicine Am. J. Med. Optimal Systolic Blood Pressure Target in Resistant and Non-Resistant Hypertension: A Pooled Analysis of Patient-Level Data from SPRINT and ACCORD. S0002-9343(18)30783-6 10.1016/j.amjmed.2018.08.005 Prior studies suggest benefits of blood pressure lowering (...) on cardiovascular risk may be attenuated in patients with resistant hypertension compared with the general hypertensive population, but prospective data are lacking. We assessed intensive (<120 mm Hg) versus standard (<140 mm Hg) systolic blood pressure targets on adverse outcome risk according to baseline resistant hypertension status, using Action to Control Cardiovascular Risk in Diabetes (ACCORD) and Systolic Blood Pressure Intervention Trial (SPRINT) patient-level data. Patients were categorized as having

EvidenceUpdates2018

11. Tai Chi exercise is more effective than brisk walking in reducing cardiovascular disease risk factors among adults with hypertension: A randomised controlled trial

Tai Chi exercise is more effective than brisk walking in reducing cardiovascular disease risk factors among adults with hypertension: A randomised controlled trial 30195124 2018 10 10 1873-491X 88 2018 Aug 24 International journal of nursing studies Int J Nurs Stud Tai Chi exercise is more effective than brisk walking in reducing cardiovascular disease risk factors among adults with hypertension: A randomised controlled trial. 44-52 S0020-7489(18)30201-3 10.1016/j.ijnurstu.2018.08.009 Physical (...) inactivity is a major modifiable lifestyle risk factor associated with cardiovascular disease. Tai Chi is a safe and popular form of physical activity among older adults, yet direct comparisons are lacking between Tai Chi and brisk walking in their ability to reduce cardiovascular disease risk factors and improve psychosocial well-being. 246 adults (mean age = 64.4 ± 9.8 years, age range = 30-91 years, 45.5% men) with hypertension and at least two but not more than three modifiable cardiovascular disease

EvidenceUpdates2018

12. Comparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic Hypertension

Comparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic Hypertension 30217371 2018 09 15 1879-1913 2018 Aug 04 The American journal of cardiology Am. J. Cardiol. Comparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic Hypertension. S0002-9149(18)31494-2 10.1016/j.amjcard.2018.07.022 Two post hoc analyses in self-identified black and white patients with hypertension evaluated the angiotensin II (...) . Ferdinand Keith C KC Heart and Vascular Institute, Tulane University School of Medicine, New Orleans, Louisiana. Electronic address: kferdina@tulane.edu. Bakris George L GL ASH Comprehensive Hypertensive Center, University of Chicago Medicine, Chicago, Illinois. Cushman William C WC Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, Tennessee. Weber Michael A MA Department of Medicine, SUNY Downstate School of Medicine, Brooklyn, New York. Lloyd Eric E

EvidenceUpdates2018

13. Cardiovascular risk model performance in women with and without hypertensive disorders of pregnancy

Cardiovascular risk model performance in women with and without hypertensive disorders of pregnancy 30209122 2018 09 13 1468-201X 2018 Sep 12 Heart (British Cardiac Society) Heart Cardiovascular risk model performance in women with and without hypertensive disorders of pregnancy. heartjnl-2018-313439 10.1136/heartjnl-2018-313439 Compare the predictive performance of Framingham Risk Score (FRS), Pooled Cohort Equations (PCEs) and Systematic COronary Risk Evaluation (SCORE) model between women (...) with and without a history of hypertensive disorders of pregnancy (hHDP) and determine the effects of recalibration and refitting on predictive performance. We included 29 751 women, 6302 with hHDP and 17 369 without. We assessed whether models accurately predicted observed 10-year cardiovascular disease (CVD) risk (calibration) and whether they accurately distinguished between women developing CVD during follow-up and not (discrimination), separately for women with and without hHDP. We also recalibrated

EvidenceUpdates2018